key: cord-1017178-7npzx1jd
authors: Masih, Anup; Agnihotri, Amol K.; Srivastava, Jitendra K.; Pandey, Nidhi; Bhat, Hans R.; Singh, Udaya P.
title: Discovery of novel pyrazole derivatives as a potent anti‐inflammatory agent in RAW264.7 cells via inhibition of NF‐ĸB for possible benefit against SARS‐CoV‐2
date: 2020-10-23
journal: J Biochem Mol Toxicol
DOI: 10.1002/jbt.22656
sha: bff40103da77c8acdab841dc7965a776cbed6064
doc_id: 1017178
cord_uid: 7npzx1jd

Due to unavailability of a specific drug/vaccine to attenuate severe acute respiratory syndrome coronavirus 2, the current strategy to combat the infection has been largely dependent upon the use of anti‐inflammatory drugs to control cytokines storm responsible for respiratory depression. Thus, in this study, we discovered novel pyrazole analogs as a potent nuclear factor kappa B (NF‐ĸB) inhibitor. The compounds were assessed for NF‐ĸB transcriptional inhibitory activity in RAW264.7 cells after stimulation with lipopolysaccharides (LPS), revealing Compound 6c as the most potent analog among the tested series. The effect of Compound 6c was further investigated on the levels of interleukin‐1β, tumor necrosis factor‐α, and interleukin‐6 in LPS‐stimulated RAW267.4 cells by enzyme immunoassay, where it causes a significant reduction in the level of these cytokines. In Western blot analysis, Compound 6c also causes the inhibition of inhibitor kappa B‐α and NF‐κB. It was found to be snugly fitted into the inner grove of the active site of NF‐ĸB by forming H‐bonds and a nonbonded interaction with Asn28 in a docking analysis.

The whole world is facing a severe unprecedented problem due to outbreak of coronavirus disease (COVID-19) caused by a positive-sense RNA virus. It is clinically termed as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and considered as an epidemic. [1, 2] Till now, it has spread to more than 215 countries/territories, affected more than 10 million people, and responsible for death of more than 500,000 since it was first reported in late December 2019 in the Wuhan, China. Concerning the seriousness of situation and spreadability, on January 31, 2020, it was acknowledged as public health crisis for all the countries by World Health Organization. [3] [4] [5] Many of the people affected by the virus do not have serious clinical complications at an early stage of infection. However, some individuals report fever, cough or chest tightness, dysopnoea and, in some cases, mild/severe illness. Moreover, the patient suddenly progresses to the late stage of the infection, observing acute respiratory distress syndrome and multiple-organ failure, which result in death within a short time. Amassing confirmations propose that cytokine storm is the main reason underlying the severity and morbidity in COVID-19 patients, where immune cells were found highly active with production of massive inflammatory cytokines and chemical mediators. [6] [7] [8] [9] SARS-CoV-2 after entering respiratory epithelial cells shows formation of a hyaline membrane and an increased infiltration of inflammatory cells with multinucleated syncytial cells. [10] [11] [12] Studies have found an aberrant activation of nuclear factor kappa B (NF-ĸB) in inflammatory responses of SARS-CoV-2 infections. [13] It has a noteworthy part within the framework of immune system by acting as a key mediator of proinflammatory gene induction and facilitating cells belonging to both innate and adaptive immune system. It corresponds to the family of inducible transcription factors, which manages various genes that have been implicated in diverse processes of the immune and inflammatory responses. It was further subdivided into five fundamentally related individuals, for instance, NF-κB1 (or p50), NF-κB2 (or p52), RelA (or p65), RelB, and c-Rel, which induce transcription of intended genes by combining with a specific DNA facet. [14] [15] [16] [17] The enactment of NF-κB may well be conceivable by the inclusion of two particular pathways, such as canonical and noncanonical (or another) pathways. Despite their contrasts in the signaling instrument, these both are considered vital for modulating immune and inflammatory responses. [18] The canonical NF-κB pathway could be activated by cytokines, growth factors, mitogens, microbial, and stress agents. Initially, it can be started by the inducible degradation of inhibitor kappa B-α (IκBα) stimulated by phosphorylation of a multisubunit IκB kinase (IKK) complex in a sitespecific manner. The IKK is further subdivided into two catalytic subunits, IKK-α and IKK-β, and NF-κB essential modulator or IKK-γ, a regulatory subunit. Studies have shown that IKK could be easily activated by the action of mitogens, growth factors, stress agent cytokines, and microbial components. [19] Upon activation, the p50/RelA and p50/c-Rel dimers (canonical NF-κB member) get translocated from cytoplasm to nucleus through the phosphorylation of IκBα at two N-terminal serines, which is further ubiquitously degraded in proteosome.

However, the noncanonical NF-κB pathway is selectively stimulated to a certain cluster of inducers, such as ligands belonging to tumor necrosis factor (TNF) receptor superfamily members, for example, CD40, BAFFR, RANK, and LTβR. [16, 20] Unlike the canonical pathway, it is not dependent on IκBα, but it may be dependent upon handling of the NF-κB2 forerunner protein (p100). Research has demonstrated the role of the canonical NF-κB pathway in nearly all areas of the immune response, whereas the noncanonical NF-κB pathway seems to be emerging as an external signaling axis operating together with the canonical NF-κB pathway to control the basic functions of the adaptive immune system. [21] [22] [23] There is currently no effective antiviral agent available to treat SARS-CoV-2 infection.

Much attention is, therefore, focused on the regulation of cytokine storm and inflammatory reactions in SARS-CoV-2 infections, such as selective inhibition of NF-ĸB.

The current medicinal chemistry has been largely dependent on the heterocyclic compounds to develop newer drugs/agents due to ease of generating chemical diversity based on pharmacological or toxicological studies. [24] Pyrazole, a nitrogen-containing heterocyclic molecule, is found to possess numerous pharmacological activities. [25, 26] It is also found in commercially successful drugs, such as celecoxib (anti-inflammatory), rimonabant (antiobesity), fomepizole (alcohol dehydrogenase inhibitor), and sildenafil (to improve erectile dysfunction). [26] [27] [28] Various recent studies have shown pyrazole as a potent inhibitor of NF-ĸB. [29] Moreover, we have also discovered some derivatives of pyrazoles as potent antibacterial [30] and anti-HIV-1 agents. [31, 32] Therefore, in the present study, in continuation of our research activity on the development of small molecule inhibitors, [33] [34] [35] we intend to develop a novel series of pyrazole as a novel NF-ĸB inhibitor for possible benefit in SARS-CoV-2 infection.

The synthesis of designed analogs has been achieved according to previously reported procedures. [36, 37] The detailed procedure for synthesis, along with analytical spectroscopic data, has been provided in Supporting Information associated with the manuscript. 

RAW264.7 cells were incubated for 10 min on ice after treating with lysis buffer. The resulting solution was centrifuged at 15,000g for 5 min at 4°C, and the resulting pellet having raw nuclei was further suspended in extraction buffer (50 μl) and then incubated for further 30 min at 4°C on a shaker. The nuclear extract was obtained (supernatant) after centrifuging the above mixture for 10 min at 16,000g.

RAW264.7 cells after incubation with Compound 6c for 2 h were stimulated for 6 h with LPS (1 μg/ml). The cells than lysed with lysis buffer and allowed to centrifuge for 5 min at 12,000g. The resulting supernatant was obtained as total protein and the concentration was calculated using a protein assay kit. Furthermore, 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis was used to separate protein samples, which were further transferred on a polyvinylidene fluoride membrane (Millipore). To block the membrane in TBST, 5% skimmed milk was used. The resulting membrane was then treated with primary antibody (1:1000) and with respective secondary antibodies (1:5000; Cell Signaling Technology). The expressions of biomarkers were observed by enhanced chemiluminescence (Thermo Fischer Scientific Inc.) kit and ImageJ software was used to analyze the bands. Moreover, for determination of various biomarkers, the membrane was exposed using stripping buffer for 15 min on a shaker. The membrane was then washed with TBST and once more blocked with skimmed milk (5%) in TBST buffer. The membrane was then blotted with primary antibody (1:1000) and with respective secondary antibodies (1:5000).

The docking study of the most active Compound 6c was conducted 

In this study, a diverse series of novel pyrazoles was devised and synthesized, as shown in Scheme 1, toward finding a potent NF-ĸB inhibitor. The comparative inhibitory activity of target compounds is shown in Table 1 . As presented in Table 1 , Compound 6a

containing p-chloro showed a considerable inhibition of NF-ĸB transcription activity in LPS-stimulated RAW264.7 cells. The inhibitory activity was declined considerably in the case of Compound 6b.

The inhibitory potency was found highest among the tested series in 

Considering the importance of various proinflammatory cytokines in SARS-CoV-2 infections, [38, 39] 

Various studies have implicated the role of NF-ĸB signaling cascade in the generation of various inflammatory cytokines in the LPS-stimulated macrophages. [40, 41] Therefore, in this part of the study, we specifically investigate whether Compound 6c could be competent enough to inhibit the activation of NF-ĸB signaling cascade and its upstream modulators, such as IκBα, by Western blot analysis. IκBα acts as a positive regulator to promote the activation of NF-ĸB signaling cascade after phosphorylation of IκB. As shown in Figure 3A ,B, Compound 6c causes a dosedependent inhibition of p-IκBα in the cytosol as compared with the LPS group. The nuclear translocation of NF-κB is a critical step for the release of inflammatory cytokines; therefore, in this part, we intend to determine the effect of Compound 6c on the nuclear translocation of NF-κB using nuclear extracts of LPSstimulated RAW264.7 macrophages. As shown in Figure 3A ,B, the F I G U R E 6 A prospective mechanism of Compound 6c as an anti-inflammatory agent. IKK, IκB kinase; IL-1β, interleukin-1β; IL-6, interleukin-6; IκBα, inhibitor kappa B-α; LPS, lipopolysaccharide; NF-ĸB, nuclear factor kappa B; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 expression of NF-κB in the nucleus was found to be increased in the LPS group, as compared with control. Moreover, as expected,

Compound 6c causes a concentration-dependent inhibition of LPS-induced nuclear translocation of NF-κB. The observation was further found to be in accordance with the potent NF-κB inhibitory activity of Compound 6c, as shown in Figure 1 . Results of the study suggested that Compound 6c causes the inhibition of release of various proinflammatory cytokines, possibly due to the inhibition of NF-κB activity.

As presented in Figure 4 , Compound 6c was found to be deeply engulfed in the active site (as shown as red sphere) of the NF-ĸB protein model. Moreover, on close inspection, it was found that Compound 6c efficiently interacted with neighboring residues via making various interatomic contacts. Compound 6c

formed one H-bond with Lys145 (Chain B) through a carbonyl oxygen atom. It also formed one π-cation interaction between phenyl linked to piperazine and Lys145 (Chain A). It was also observed to interact with Cys59, Thr153, Lys144, His141, and

Tyr57 of Chain B in Figure 5 . The results were further found in agreement with previous studies where potent NF-ĸB inhibitors interacted in a similar fashion. [42] On the basis of above studies, it is concluded that Compound 6c can attenuate inflammatory cascade via inhibiting number of mediators, as depicted in Figure 6 .

Collectively, in our present study, we have showed the development of novel pyrazole derivatives as a potent anti-inflammatory agent by inhibiting NF-ĸB activation in LPS-stimulated RAW264.7

cells. Results showed Compound 6c as the most potent inhibitor of NF-ĸB transcription activity, which causes a significant inhibition of various proinflammtory cytokines, and a positive regulator of NF-ĸB activation (IĸBα). Thus, Compound 6c could be suggested as a potential lead for therapeutic application in controlling the inflammatory response in SARS-CoV-2 infection.

All the authors are thankful to SHUATS for providing necessary infrastructural facilities.

Discovery of novel pyrazole derivatives as a potent anti-inflammatory agent in RAW264.7 cells via inhibition of NF-ĸB for possible benefit against SARS-CoV-2

The authors declare that there are no conflict of interests. Udaya P. Singh https://orcid.org/0000-0003-0865-0502